SG11202002841PA - Semaglutide in medical therapy - Google Patents
Semaglutide in medical therapyInfo
- Publication number
- SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA
- Authority
- SG
- Singapore
- Prior art keywords
- semaglutide
- medical therapy
- therapy
- medical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002841PA true SG11202002841PA (en) | 2020-04-29 |
Family
ID=60083831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002841PA SG11202002841PA (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US12029779B2 (enExample) |
| EP (1) | EP3694538A1 (enExample) |
| JP (2) | JP7148605B2 (enExample) |
| KR (1) | KR20200069316A (enExample) |
| CN (4) | CN119838000A (enExample) |
| AU (2) | AU2018348929B2 (enExample) |
| BR (1) | BR112020006246A2 (enExample) |
| CA (1) | CA3078652A1 (enExample) |
| CL (1) | CL2020000812A1 (enExample) |
| IL (3) | IL322968A (enExample) |
| MA (1) | MA50358A (enExample) |
| MX (3) | MX2020003049A (enExample) |
| MY (1) | MY204827A (enExample) |
| PH (1) | PH12020550185A1 (enExample) |
| SG (1) | SG11202002841PA (enExample) |
| TW (1) | TWI842681B (enExample) |
| WO (1) | WO2019072941A1 (enExample) |
| ZA (3) | ZA202503387B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322968A (en) * | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical treatment |
| MX2022009844A (es) * | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Composiciones y usos del peptido similar al glucagon-1 (glp-1). |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| WO2022212268A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| US20240404673A1 (en) * | 2023-06-05 | 2024-12-05 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | 修飾ｇｌｐ−１の安定な処方剤 |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| PL3300721T5 (pl) | 2003-11-20 | 2025-11-17 | Novo Nordisk A/S | Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania |
| ES2735533T3 (es) | 2004-11-12 | 2019-12-19 | Novo Nordisk As | Formulaciones estables de GLP-1 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR101486829B1 (ko) | 2005-09-14 | 2015-01-29 | 맨카인드 코포레이션 | 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법 |
| BRPI0709964A2 (pt) | 2006-04-14 | 2011-08-02 | Mannkind Corp | formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1) |
| WO2008116088A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| SI2373681T1 (sl) | 2008-12-10 | 2017-05-31 | Glaxosmithkline Llc Corporation Service Company | Farmacevtski sestavki albiglutida |
| EA029759B1 (ru) | 2009-02-13 | 2018-05-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами |
| HUE027229T2 (en) | 2009-12-16 | 2016-08-29 | Novo Nordisk As | Double acylated glp-1 derivatives |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| HRP20180425T1 (hr) | 2010-12-16 | 2018-04-20 | Novo Nordisk A/S | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| US8975223B2 (en) | 2010-12-22 | 2015-03-10 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146 |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| WO2012177929A2 (en) | 2011-06-24 | 2012-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| JP6250034B2 (ja) * | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| JP6059802B2 (ja) * | 2012-07-01 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 長時間作用型ｇｌｐ−１ペプチドの使用 |
| ES2688462T3 (es) * | 2013-05-02 | 2018-11-02 | Novo Nordisk A/S | Dosificación oral de compuestos de GLP-1 |
| CN109715662B (zh) | 2015-12-23 | 2023-07-21 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
| IL322968A (en) * | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical treatment |
-
2018
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US20250235511A1/en active Pending
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-05-15 AU AU2025203535A patent/AU2025203535A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260383B (en) | Low dose medication | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| IL253712B (en) | Mysterlein derivatives for coupling and healing | |
| IL273470A (en) | Semaglutide in medical treatment | |
| IL260771B1 (en) | Catheter closure solution and catheter closure treatment | |
| SG11201707816PA (en) | Patient interface and aspects thereof | |
| IL250990A0 (en) | Materials for human care | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| IL257173A (en) | New insulin histories and their medical uses | |
| SG10202010420TA (en) | Patient interface and aspects thereof | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| GB201709840D0 (en) | Methods and medical uses | |
| PL3253208T3 (pl) | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi | |
| IL247969B (en) | A medicinal component for use in the treatment of infections | |
| GB201513097D0 (en) | Medical implant | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| PT3325478T (pt) | Novo composto terapêutico e a utilização em terapia | |
| GB201607594D0 (en) | Patient stimulation device | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| HK40026666A (en) | Semaglutide in medical therapy | |
| GB2543288B (en) | Tiltable implantable medical device | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment | |
| GB201709837D0 (en) | Methods and medical uses |